BRISTOL, Tenn., July 15 /PRNewswire-FirstCall/ -- King Pharmaceuticals,
Inc. (NYSE: KG) reported today that the Company plans to announce financial
results for the second quarter ending June 30, 2004, prior to the market open
on Thursday, August 5, 2004. Conference call information will be provided
when available via a subsequent press release.
King, headquartered in Bristol, Tennessee, is a vertically integrated
pharmaceutical company that develops, manufactures, markets, and sells branded
prescription pharmaceutical products. King, an S&P 500 Index company, seeks
to capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions, of
novel branded prescription pharmaceutical products in attractive markets and
the strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management.
This release contains forward-looking statements that reflect management's
current views of future events and operations, including, but not limited to,
statements pertaining to the anticipated date for release of the Company's
financial results for the second quarter ending June 30, 2004. These forward-
looking statements involve certain significant risks and uncertainties, and
actual results may differ materially from the forward-looking statements. An
important factor that may cause results to differ is whether King is able to
release the Company's financial results for second quarter ending June 30,
2004 as currently planned on August 5, 2004. King does not undertake to
publicly update or revise any of its forward-looking statements even if
experience or future changes show that the indicated results or events will
not be realized.
SOURCE King Pharmaceuticals, Inc.
 back to top
Related links:
http://www.kingpharm.com
Company News On-Call:
http://www.prnewswire.com/comp/120319.html
CONTACT:
James E. Green, Executive Vice President,
Corporate Affairs of King Pharmaceuticals, Inc., +1-423-989-8125
|
